Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
43 hedge funds and large institutions have $3.1M invested in Accelerate Diagnostics in 2025 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 12 reducing their positions, and 7 closing their positions.
250% more call options, than puts
Call options by funds: $7K | Put options by funds: $2K
9% less funds holding
Funds holding: 47 → 43 (-4)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
45% less capital invested
Capital invested by funds: $5.69M → $3.1M (-$2.58M)
50% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lido Advisors
Los Angeles,
California
|
+$186K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$29.2K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$11.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$7.73K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$1.66K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$227K |
| 2 |
GAM
Griffin Asset Management
New York
|
-$172K |
| 3 |
Renaissance Technologies
New York
|
-$48.8K |
| 4 |
Jane Street
New York
|
-$26.9K |
| 5 |
Millennium Management
New York
|
-$17.9K |
AXDX Hedge Fund Activity: Q1 2025 in Review
43 of the 7,471 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q1 2025, worth a combined $3.1M — down 45% from $5.69M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AXDX and 4 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 6 added.
The largest buyer was Lido Advisors, opening a new position worth an estimated $186K. The largest seller was Armistice Capital, cutting an estimated $227K.
- 43 institutional investors held Accelerate Diagnostics (AXDX) as of Q1 2025, down from 47 in Q4 2024.
- Funds reported $3.1M of Accelerate Diagnostics stock for Q1 2025, down 45% quarter-over-quarter.
- 4 funds opened new Accelerate Diagnostics positions in Q1 2025 and 7 closed out, a net change of -3 holders.
- The largest Accelerate Diagnostics buyer in Q1 2025 was Lido Advisors, an estimated $186K added.
- The largest Accelerate Diagnostics seller in Q1 2025 was Armistice Capital, an estimated $227K sold.
Based on aggregated 13F filings for Q1 2025.